Announced Wed, 22 Jul · 13:40 IST
Transgene Biotek says Reg 32 deviation report not applicable for Q1 FY27
Compliance View source PDF
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Price reaction · full curve 14 horizons · vs prior close
-2.0%1-day move
₹3.05
prior close
—
base price
In-mkt
timing
5m10m15m30m1D2D3D4D5D7D15D1M2M3M
————-2.0+0.0-1.6———————
Up moveDown movePending
AI summary
Transgene Biotek has informed BSE that Regulation 32(1) deviation or variation statement is not applicable for the quarter ended 30 June 2026. The company states there was no public issue, rights issue, preferential issue, or QIP during the quarter, so no deviation report is required. It is submitting the intimation in non-XBRL mode since the form does not allow NIL entry. Signed by Chairman and Managing Director Dr K Koteswara Rao.
Likely market impact
Routine compliance filing with no impact on operations or shareholders; confirms no fresh capital was raised in the quarter.